On-chain data reveals top crypto to buy before August ends. Learn why Moonshot MAGAX, with its deflationary tokenomics, could outperform ETH and XRP.On-chain data reveals top crypto to buy before August ends. Learn why Moonshot MAGAX, with its deflationary tokenomics, could outperform ETH and XRP.

On-Chain Data Reveals Crypto to Buy Before August Ends: Why Moonshot MAGAX Could Outpace ETH and XRP

rocket-blackblue image 2 34

Crypto Market’s Narrative: Why Investors Are Ditching Large Caps for Emerging Projects

Ethereum and XRP are leading a new market surge, but many investors are looking for the next breakout star. On-chain data points to a potential new contender: Moonshot MAGAX, a hybrid token that blends meme appeal with real-world utility. 

This shift is driven by a desire for asymmetric returns that are no longer realistic for large-cap assets. On-chain metrics reveal a significant rotation of capital from established coins into emerging projects, suggesting a hunt for the next exponential growth story.

Ethereum Holds Strong but Faces Market Uncertainty

Ethereum continues to dominate the decentralized finance and smart contract landscape, currently trading at $4,300. Despite its strength, congestion issues and high gas fees have limited its near-term growth potential. 

This market uncertainty creates a window of opportunity for projects offering innovative solutions. Ethereum’s upcoming upgrades aim to address scaling, but the uncertain timeline leaves room for newer projects like Moonshot MAGAX, which aren’t weighed down by legacy limitations.

XRP Consolidates Gains Around $3.01

XRP currently trades at $2.80, reflecting stability after a wave of gains that followed regulatory clarity in the U.S. This price consolidation is a double-edged sword; it signals healthy strength but also suggests slower near-term growth compared to smaller, emerging tokens. 

With a large portion of XRP holders in profit, analysts warn that a wave of profit-taking could create resistance, shifting some investor focus toward low-cost presale tokens with more potential for large gains.

On-Chain Data Signals Growing Retail Activity

Blockchain data reveals a notable uptick in wallet creation and activity among smaller investors, often seen as a precursor to retail-led rallies. Historically, retail enthusiasm has been a key driver of explosive growth for meme and community-focused coins. 

MAGAX fits perfectly into this trend, combining affordability with strong narrative potential. Its low entry price makes it an appealing option for retail investors betting on massive returns once it hits exchanges.

Positive Comparisons Strengthen MAGAX’s Case

Market analysts are drawing comparisons between Moonshot MAGAX and the early stages of Dogecoin and Shiba Inu. These meme tokens famously turned small investments into life-changing returns, highlighting the power of community. The key difference, however, lies in MAGAX’s added AI-driven functionality. Unlike its predecessors, MAGAX isn’t just about hype—it also integrates real-world utility, giving it both meme appeal and practical staying power.

image 2 33

MAGAX: An Asymmetric Investment Opportunity

Currently priced at just $0.00027, MAGAX offers one of the lowest entry points among emerging tokens. Early projections from market watchers suggest it could climb to $0.10 in the medium term, with the long-term potential to reach $1 if adoption accelerates. 

This potential for up to 3,600x returns from current presale prices far outpaces what established tokens like XRP or Ethereum can realistically deliver. With a deflationary tokenomic structure and staking rewards, MAGAX offers a sustainable growth model unlike many meme coins that rely solely on hype. The project’s successful Certik Audit Certificate provides investors with additional trust in its security and code reliability.

A Shift in Investor Strategy

While Ethereum and XRP showcase remarkable strength and institutional backing, the real story for many investors is the search for the next high-growth opportunity. The market is witnessing a clear trend of capital moving into promising new projects like MAGAX that offer both utility and the potential for explosive returns. 

This shift highlights a growing appetite among investors to diversify their portfolios with tokens that combine established market principles with innovative, community-driven use cases.

Be part of the Moonshot Magax Presale Community:

Website | Whitepaper | Telegram | X (Twitter)

Market Opportunity
Brainedge Logo
Brainedge Price(LEARN)
$0.0093
$0.0093$0.0093
-1.58%
USD
Brainedge (LEARN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26